Idiopathic Pulmonary Fibrosis

February 22, 2016May 13, 2016

IPF Therapy Capable of Halting Fibrosis Is Goal of Newly Launched Company, Pliant Therapeutics

Third Rock Ventures, LLC, announced the launch of a new biotechnology company, Pliant Therapeutics, Inc., with $45 million in Series A financing. Pliant plans to develop drugs for the treatment of fibrotic ... Read more

February 11, 2016February 18, 2016

Regardless of IPF Diagnosis, Acute Respiratory Worsening Is an Independent Factor That Increases Morbidity, Study Suggests

Idiopathic Pulmonary Fibrosis, News

In a recent study, “Patients with Fibrotic Interstitial Lung Disease Hospitalized for Acute Respiratory Worsening: A Large Cohort Analysis,” published in the CHEST journal, researchers reported that acute respiratory worsening ... Read more

January 29, 2016February 3, 2016

British Health Institute Recommends OFEV for Adults with IPF

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim recently announced that the British National Institute for Health and Care Excellence (NICE) has recommended OFEV (nintedanib) as a therapy for adult patients with idiopathic pulmonary fibrosis (IPF) within the National ... Read more

January 27, 2016January 27, 2016

3 Lung Researchers at UT Health Awarded $665K to Advance Work

Idiopathic Pulmonary Fibrosis, News

UT Health Northeast recently announced that four of its scientists have been awarded a total of $2.1 million in competitive grants to conduct research in projects related to lung and heart diseases. ... Read more

January 26, 2016January 26, 2016

IPF Patients Treated with Immunosuppressants, Steroids at Higher Risk During Flares

Idiopathic Pulmonary Fibrosis, News

Patients with idiopathic pulmonary fibrosis acute exacerbation (IPF-AE) who are treated under a protocol free of both immunosuppressants and steroids are significantly more likely to survive the flare than those given these ... Read more

January 26, 2016January 26, 2016

New Respiratory Therapy’s Clinical Program Getting European Patent Protection

COPD, Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company specializing in the development of drugs and devices for cardiopulmonary conditions, recently announced that the European Patent Office has issued a Notice of Intention ... Read more

January 25, 2016May 12, 2016

Upcoming American Thoracic Society Conference on Pulmonary Diseases

Asthma, COPD, Idiopathic Pulmonary Fibrosis, Lung Cancer, News, Pulmonary Hypertension

The American Thoracic Society (ATS) is inviting all those who are interested to its 2016 International Conference at the Moscone Center in San Francisco, on topics such as pulmonary, critical ... Read more

January 18, 2016January 19, 2016

Drug’s Safety for Idiopathic Pulmonary Fibrosis Supported by 5 Clinical Trials

Idiopathic Pulmonary Fibrosis, News

Research from an international, collaborative group of scientists, led by researchers at Vanderbilt University in Tennessee, supports the safety of pirfenidone as a therapy for idiopathic pulmonary fibrosis (IPF). The ... Read more

December 15, 2015December 15, 2015

New IPF Study to Test OFEV/Esbriet as Combination Therapy

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim announced that it has initiated a 12-week clinical trial investigating the safety, tolerability, and pharmacokinetics of pirfenidone (marketed as Esbriet by Genentech) as an add-on to treatment with OFEV (nintedanib). The ... Read more

December 7, 2015December 7, 2015

PFF Care Center Network Expands to 19 New Sites

Idiopathic Pulmonary Fibrosis, News

The Pulmonary Fibrosis Foundation (PFF) recently announced that 19 sites have been added to its Pulmonary Fibrosis Care Center Network, for a total of 40 sites in 26 states. The network a ... Read more